Exelixis beats third-quarter estimates and maintains 2026 revenue guidance
Exelixis reported third-quarter 2026 results on October 29, with revenue of $658.7M and non-GAAP diluted EPS of $0.94, both ahead of estimates. GAAP diluted EPS was $0.85, while U.S. cabozantinib franchise net product revenue reached $605 million, up 11% year over year. The company maintained its full-year 2026 revenue guidance at $2.50B-$2.55B and expects topline results from the phase 3 STELLAR-304 trial in the first quarter of 2027.
Why it matters
The results reinforce cash generation from Exelixis' cabozantinib franchise while the company continues investing in zanzalintinib trials. Exelixis also repurchased approximately $250 million of stock in the quarter, but its maintained revenue outlook was described as slightly below analyst consensus in one report.
Key facts
- 1Exelixis reported third-quarter revenue of $658.7M and non-GAAP EPS of $0.94. seekingalpha.com
- 2GAAP diluted EPS was $0.85 for the third quarter. investing.com
- 3Full-year 2026 revenue guidance was $2.50B-$2.55B. investing.com
- 4U.S. cabozantinib franchise net product revenue was $605 million, up 11% year over year, while global franchise revenue was $818 million. finance.yahoo.com
- 5Exelixis repurchased approximately $250 million of common stock during the third quarter. finance.yahoo.com
- 6The company expects topline results from the phase 3 STELLAR-304 trial in the first quarter of 2027. stocktitan.net
Open questions
- Material 2 describes $605M as Q3 2026 revenue in its summary, while other materials identify $605M as U.S. cabozantinib franchise revenue and $658.7M as total revenue.
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.